Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The new screenshot shows minor formatting and layout changes with no substantive updates to the study details, outcomes, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:25:25.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    41 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.
    Difference
    3%
    Check dated 2025-10-06T05:56:45.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Replaces/phases out pharmaceutical-solution categories with broader chemical categories and updates the version to v3.1.0; several prior solution-related terms are removed.
    Difference
    0.9%
    Check dated 2025-09-29T03:12:51.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The page revision is updated from v3.0.1 to v3.0.2, and the Back to Top element has been removed. There are no changes to core content, pricing, stock, or time-sensitive information.
    Difference
    0.2%
    Check dated 2025-09-14T19:53:12.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T16:54:49.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as new content related to drug safety and various types of solutions. The previous location details and revision information have been removed.
    Difference
    1%
    Check dated 2025-08-31T12:10:41.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.